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1 INTRODUCTION AND
BACKGROUND
From the earliest days of the COVID-19 pandemic, dental
practitioners, organizations, educators, insurers, andman-
ufacturers were concerned about the impact of the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
on a panoply of issues, including transmission modes; per-
sonal protective equipment (PPE) supplies; aerosolization;
office disinfection; patient confidence; and screening and
testing protocols to determine the viral status of patients,
clinicians, and staff members. The shared goals of den-
tal clinicians were to treat patients as safely as possible
through optimal use of PPE with disinfection and aerosol
mitigation protocols to minimize the risk of viral trans-
mission in the dental office or school clinic. Since initial
state and federal pandemic efforts focused on treating the
sickest patients, hospital capacity, mass testing, and the
global PPE supply, a group of dental schools recognized
that dental practices would benefit greatly from the ability
to evaluate the viral status of their patients using office-
based, point-of-care (POC) tests, ideally using sputum,
saliva, and/or finger stick blood samples. Since private
dental offices and most dental schools lack the analytic
instrumentation and theClinical Laboratory Improvement
Amendment (CLIA) certifications to conduct the types of
polymerase chain reaction (PCR) viral tests prevalent in
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the early days of the outbreak, the group of schools focused
on POC tests, which did not require CLIA certified labs or
expensive equipment.
The Collaborative consisted of the dental schools from
the University of California, San Francisco; the University
of Michigan; Temple University; the University of Penn-
sylvania; Rutgers University; and New York University. In
addition, the respected health care company Henry Schein
Inc., provided market insights and a gateway to the many
manufacturers developing tests, and the Santa Fe Group
helped coordinate the efforts of the Collaborative and
promulgate the findings. Importantly, all tests considered
by the Collaborative were “platform neutral,” meaning
that any manufacturer that could provide an accurate
POC test would be considered for use. A small group of
physicians and dentists served in an advisory capacity,
and the group operated as the Testing for Tomorrow (T4T)
Collaborative.
With knowledge about the virus expanding continu-
ously, new tests arriving almost daily, the FDA recall of
scores of flawed tests, and schools under constraints from
clinic closures and PPE shortages, it was a struggle to
evaluate the tests and to establish supporting protocols.
The initial goal of identifying the best POC test—be it
antigen, antibody, or viral—was elusive, although each
school did identify alternative approaches to evaluate
their students, faculty, staff, and patients, and developed
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careful approaches to re-opening their clinics. Thus,
while the initial primary goal has not been met, each
participating institution in T4T benefited substantially
from the shared experience of working through patient
assessment protocols, validation testing, and access to
content experts and new tests that would not have been
readily available to a single institution. Thus, perhaps the
most important perspective to consider is that educational
institutions should seek the benefits of collaborating in
small groups, especially in the fast-paced environment
where completely novel challenges are forced upon
them.
2 GOALS OF THE T4T
COLLABORATIVE
The T4T Collaborative set the following goals:
1. Recruit intra-institutional and interinstitutional part-
ners, including community-based entities, to develop
COVID-19 evaluation protocols for first responders,
frontline healthcare professionals, essential workers,
and ultimately patients and private practice staff.
2. Evaluate SARS-CoV-2 tests that are appropriate for use
in clinical practice with primary emphasis on those
POC tests that would be most useful in private practice
settings.
3. Provide guidance on lessons learned and recommend
best practices to both healthcare institutions and the
practitioner community.
3 FACTORS ANTECEDENT TO
ACTUAL TESTING
An institution desiring to conduct COVID-19 testing
should first identify the individuals to be tested (e.g.,
patients, students, staff, faculty), and then appoint a
leader and key personnel from IT, patient services, and
the clinical faculty. If state law does not allow dentists
to perform COVID-19 tests, the dental school will need
to collaborate with other authorized health providers.
Finally, it should select an FDA Emergency Use Autho-
rization (EUA) approved COVID-19 test, and a convenient
testing location separated from patient clinics or waiting
areas.
IT staff can create online recruitment, prescreening and
scheduling tools. Also, they can add systems in the elec-
tronic health record to allow medical insurance billing,
record essential COVID-19 related patient information,
report test results to state and federal health authorities,
and track patients for retesting as necessary.
Informed consent and test results (including posttest
recommendations based on federal, state, and local guid-
ance) forms must be created. The Centers for Disease
Control and Prevention (CDC) recommends that asymp-
tomatic individuals with a positive COVID-19 viral test
must quarantine for 7 to 10 days after the first labora-
tory confirmed positive test. If symptomatic, individuals
must quarantine for 7 to 10 days since symptoms first
appeared, and 24 hours with no fever without the use of
fever-reducingmedications, and symptoms have improved
(e.g., cough, shortness of breath). Some organizations also
require a negative COVID-19 test to return to work or
school. Positive test results should be referred to local
health authorities for contact tracing.
Training is crucial for testing accuracy, data integrity,
and safety. Training should include how to perform entry
screening, collect specimens, load test devices, read test
results, enter data, and communicate results to patients.
Creating checklists to avoid errors, and videos of the test-
ing procedures, have proven helpful. An infection control
officer should be consulted regarding necessary PPE and
proper donning and doffing of PPE by staff in the testing
location.
When all of this preparation is done, testing can com-
mence.
4 SARS-CoV-2 TEST CONSIDERATIONS
4.1 Molecular testing
Molecular testing is considered themost sensitive and spe-
cific of the SARS-CoV-2 tests. It detects the presence of
ribonucleic acid (RNA), the genetic material associated
with the virus, and is used to determine the presence of
an active infection.
Initial efforts to detect SARS-CoV-2 used standard PCR
methods that were accurate but time consuming and
required equipment and trained personnel. Thus, these
methods had limited utility due to the high demand, slow
response time, expense, and required laboratory expertise.
Although this method remains the gold standard, it is
impractical for high volume, rapid testing.
Since SARS-CoV-2 is an RNA virus, the first step is
to use reverse transcriptase to convert the RNA to DNA.
Briefly, after initial isolation from an infected patient,
the SARS-CoV-2 RNA virus is separated from human
DNA, reversed, and transcribed into cDNA for PCR
amplification. In the process, PCR primers for the spike
protein (S) for viral attachment and penetration of human
cells, the envelope protein (E), the matrix protein (M),
and the nucleocapsid protein (N) were identified. Once
converted to DNA, any of the proteins (S, E, M, or N) can
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TABLE 1 Comparison of PCR and LAMP





































be amplified via PCR primer amplification. This process
was simplified by combining step 1 (reverse transcription)
and step 2 (cDNA) prior to amplification. In this 1-step
procedure, PCR amplification was accomplished via
cycles of thermal changes (high temps to low temps).
The number of cycles and times for each cycle can be
used to determine the amount of DNA amplification.
Newer methods use isothermal amplification, a constant
temperature, and less equipment, and show promise for
POC testing. Loop mediated isothermal amplification
(LAMP) is shown below as 1 example (see Table 1).
Other methods using CRISPR technology and terahertz
time-domain spectroscopy are also being evaluated for
POC rapid testing, but none of these methodologies are
approved for use currently.
4.2 Antigen testing
Antigen testing, likemolecular testing, is designed to iden-
tify active infection, but it detects the presence of viral pro-
teins, not viral RNA. Antigen tests are typically somewhat
less sensitive than are molecular tests but can often be less
expensive and faster to run.
POC testing for antigens requires that samples are taken
from the patient on site. Commonly, a plate or slide is pre-
coated with an antibody designed to capture a variety of
SARS-CoV-2 antigens (S, N, M, or E). The antibody-coated
plate then reacts with the chosen antigen to capture the
antigen on the plate. The captured antigen is then reacted
with a secondary antibody linked to an enzyme that will
also reactwith the antigen.Ultimately, a colorimetric agent
is applied to the enzyme containing secondary antibody,
which will indicate the presence of the SARS-CoV-2 anti-
gen in the patient sample. This is done either as a lat-
eral flow method, where the process proceeds on a matrix
that allows for antigen capture from a patient sample to
migrate on the plate, or in an Enzyme Linked Immunoas-
say (ELISA), which requires a 96 well plate and a reader, in
addition to several washing steps. The lateral flow method
is usually qualitative (dichotomous – negative or positive –
or ordinal – negative, weakly positive, or strongly positive)
or semiquantitative (e.g., subjectively rated 0= negative, 1,
2, 3, 4, 5, 6= strongly positive), while the ELISA test can be
quantitative.
4.3 Antibody testing
Whereas viral (antigen or molecular) testing detects cur-
rent infection, antibody testing detects evidence of past
infection by finding antibodies specific to SARS-CoV-2
after a suitable latent period.
Antibody testing usually requires a blood or salivary
sample from the patient. This can be obtained froma finger
stick or from a peripheral blood draw. In this case, the anti-
gen (S, E, N, M) is bound to the plate or lateral flow device
as the first step. The serum derived from the blood draw is
placed on the plate or matrix, allowed to react, and then
the secondary antibody to human antisera derived from
the blood draw is reacted with either rabbit or mouse anti-
human immunoglobulin (Ig) M or IgG. The bound sec-
ondary antibody is linked to an enzyme that reacts with a
colorimetric signal that produces a response and indicates
whether the subject has antibody to SARS-CoV-2 or not.
The antibody response has several drawbacks. It does
not necessarily measure neutralizing antibody, so it may
indicate that the patient reacted by producing antibod-
ies, and therefore was exposed to the virus, but it does
not determine whether the virus is neutralized. The likely
value of antibody testing is (1) to determine if patients
do have neutralizing antibody (depending on the anti-
gen used) and thus can be used as convalescent serum to
treat infected patients; and (2) for seroprevalence studies—
determining objectively the presence of antibodies, and
therefore past infection, in populations. Neutralizing anti-
body presence can only be definitively determined in viral
neutralization/functional assays done in a biosafety level 3
facility with highly trained personnel.
Figure 1 provides a comparison of FDA EUA-approved
tests that are currently available as well as some additional
tests in development, seeking EUA approval.
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F IGURE 1 Comparison of FDA EUA-approved tests currently available or in development
5 OPENING SCHOOLS AND DENTAL
CLINICS IN THE ABSENCE OF IDEAL
TESTS
Before the COVID-19 pandemic, donning readily available
PPE had been the standard protection of dental providers
and patients. The new SARS-CoV-2 (COVID-19) pandemic
presented new challenges. Without the ability to perform
quick, highly accurate SARS-CoV-2 viral/antibody testing,
which can identify who is potentially infectious, schools
have to exclude patients with COVID-19 symptoms, or
diagnosed active cases, from routine clinical care, and
adopt universal precautions, assuming that all others (stu-
dents, faculty, staff, and patients) may be carrying the virus
without symptoms.
Guidance for reopening dental schools is limited. There
is little scientific evidence verifying the effectiveness of
strategies to reduce the spread of COVID-19, and it is not
feasible for schools and dental clinics to implement all pos-
sible strategies. Research is critically needed to determine
which strategies are the most effective and necessary to
create the safest environment.
Schools have selected actions based on prevalence of dis-
ease in their locales; the design and engineering capabili-
ties of their facilities; the availability of supplies; and the
recommendations and policies of their parent universities,
cities, counties, and states. Thus, each school has imple-
mented a unique combination of a variety of the following
approaches:
∙ Good COVID-19 personnel hygiene: Donning masks,
social distancing, and hand sanitation.
∙ Social Distancing: Online education and administra-
tion of tests, restriction on patients in waiting rooms
and cafeterias, small-group meetings with social dis-
tancing, sneeze guards to separate workstations, signage
to guide people, and teledentistry to reduce the need for
in-person visits.
∙ Symptom Checking: On the day before appointments,
and at entrances to the building or clinics, including
temperature measurements, on the day of the appoint-
ment.
∙ Enhanced PPE: Depending on the dental proce-
dure, donning of surgical masks, fitted N95 masks,
face shields, ASTM level 2/3 gowns, gloves, bouf-
fant, and shoe covers are all recommended or
required.
∙ Facility and environmental system alterations:
Temporary negative pressure or AIIR (Airborne Infec-
tion Isolation Rooms) rooms, HEPA or Minimum Effi-
ciency Report Value of 13 or higher filters and increased
air exchanges.
∙ Disinfection: Using Environmental Protection Agency
(EPA)-registered disinfectants that have qualified under
EPA’s emerging viral pathogens program for use against
SARS-CoV-2 to disinfect treatment areas before and
after dental treatment, as well as high-touch sur-
faces after each patient visit or several times during a
day.
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∙ SARS-CoV-2 Molecular/Antibody/Antigen Test-
ing: Testing students as a requirement to return to
campus, and testing patients, should be considered.
∙ Contact tracing: Effective risk assessment and swift
contact tracing as needed.
∙ No Travel Policy/Mandatory “Quarantine”: for stu-
dents/faculty/staff coming from regions with high posi-
tivity rates.
∙ Minimizing Aerosol: 4-handed dentistry, high-speed
evacuation units, minimally invasive techniques,
restricted use of ultrasonic scalers, and clinics created
with aerosol mitigation or protocols.
∙ Drive-thru Care Delivery: Some practices and clin-
ics have adopted drive-thru care, similar to drive-thru
COVID-19 testing, for screening and preventive care
(e.g., fluoride varnish application, silver diamine fluo-
ride application).
6 T4T COLLABORATIVE OUTREACH
The T4T Collaborative partners have learned much in the
process and have begun to share this learning and argue
for improvements in the system. For example:
∙ T4T submitted a request to the Office of the Surgeon
General for dentists to get access to SARS-CoV-2 tests
and reimbursement for such tests like other health pro-
fessionals.
∙ Some members of T4T presented testing protocols in a
webinar sponsored by AON, which was attended by rep-
resentatives of 700 major corporations.
∙ Several members of T4Twill share their experiences in a
webinar sponsored by the Organization for Safety, Asep-
sis and Prevention shortly after this paper is submitted.
It is expected that the T4T Collaborative will produce at
least 1 more publication after it has identified and evalu-
ated appropriate tests. This paperwill be oriented to private
practitioners andwill be available in a suitable publication.
7 SUMMARY
Although only 2 of the 3 T4T Collaborative goals have
been met to date, the participants in the effort consider
that the collaboration has been very successful and well
worth their time. As enormous amounts of information
about COVID-19 were generated worldwide, participants
from each of the 6 dental schools, plus the corporate
and not-for-profit partners, were able to evaluate rapidly
developing information using a shared group skill set
that would not have been available to a single institution.
These skills were sharedwith a remarkable esprit de corps.
Moreover, the partnership with a large, respected health
company created access to new tests, in some cases before
they were available for sale, so that validation exercises
could begin early. In addition, the schools shared infor-
mation about how to approach clinic reopening as safely
as possible in the absence of an appropriate POC test. In
sum, the use of a multischool collaborative is a powerful
mechanism that should be used when unique challenges
to dental education arise in the future. Finally, while the
perspectives contained herein are current as of the publi-
cation submission date, all institutions are encouraged to
check the websites of relevant organizations regularly for
important policy updates (e.g., CDC, FDA, WHO, OSHA,
etc.).
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